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ABSTRACT
Objective: The objective of this research work is to explore the use of liquisolid technique in enhancement of acyclovir dissolution rate. This current 
study was planned to assess the impact of different formulation variables, such as non-volatile liquid type and concentrations of acyclovir on its 
dissolution rates profile.
Method: Acyclovir liquisolid tablets were prepared with Tween 60 (liquid vehicle), Microcrystalline cellulose PH 102 (acted as a carrier to turn liquid 
medication into free-flowing powder) and Syloid XDP (coating material). In vitro, drug dissolution rate of liquisolid formulations of acyclovir was 
performed and compared with pure acyclovir drug using USP dissolution apparatus (Type II) for 60 min at a paddle speed of 50 rpm and filled with 
900 mL of distilled water.
Results: The dissolution study showed that 94.1% of the drug was released in 60 min of ratio 10 while only 66% of the pure drug acyclovir was 
released in 60 min. Hence, present work concluded that the acyclovir dissolution rate profile has been improved with the formation of liquisolid 
formulations.
Conclusion: From the present study, it may be ratified that the drug dissolution rate of acyclovir has been improved with the utilization of liquisolid 
formulations approach.
Keywords: Acyclovir, Dissolution, Non-volatile liquid, Liquisolid tablets.
INTRODUCTION
Nowadays, low solubility is the principle issue related with new drug 
moieties which should be overcome. The vast majority of the procedures 
that have prevailing with regard to conquering this issue are spray 
drying, micronization approach, β-cyclodextrins inclusion complexes, 
solid dispersions, and eutectic mixtures. However, among all, the 
feasible and financially savvy is liquisolid system. In liquisolid strategy, 
the drug is held in a solubilized state and molecularly dispersed in a 
liquid which helps to achieve the improved drug dissolution [1].
To overcome the bioavailability issue of poorly soluble drugs due 
to insufficient dissolution rate, numerous techniques are being 
utilized. Hydrophilic polymers as solubility enhancers are used 
in various approaches which perform through many ways in the 
development of various techniques such as cosolvency and inclusion 
complexes which provide numerous advantages toward formulation 
development. However, most of the time, during storage, these 
techniques show stability issues, and low industrial viability and are 
not commercially successful. Moreover, these techniques suffered 
with limitations such as hygroscopic and sticky mass which lead to 
poor flow of powders [2].
Liquisolid technology emerged as a new drug delivery system, 
differentiated due to its features and potential to deliver numerous 
drugs. These systems have drawn the attention of pharmaceutics 
scientists and scholars in the area of poorly soluble drugs for their 
solubility enhancement and controlled dissolution profile as per the 
formulation requisite [2]. This technology is patented by Spireas 
et al., in 1999, and is a simple process of physical mixing with selected 
excipients which turns it into a free-flowing, dry powder. The main 
formulation components of liquisolid systems are non-volatile liquid 
vehicle, a carrier, and a coating material. Moreover, as per the objectives 
and need of the study, sometimes other excipients such as disintegrants 
or superdisintegrants are used [3-5].
One of the anticipated mechanisms for the enhance the dissolution 
rate of the drug from the liquisolid compact mass is the wettability 
of the latter in the dissolution media. The component that helps in 
the wetting of drug particles in liquisolid system is the non-volatile 
solvent [6]. These solvent systems reduce the interfacial tension 
which was exist between the tablet surface and selected dissolution 
medium which results in increase effective surface area and wettability 
for dissolution [7]. Due to this fact, these liquisolid compacts show 
improved dissolution profile and enhanced bioavailability of poorly 
soluble drugs. The release of drug from these liquisolid compacts is 
mainly depends on few parameters, such as drug characteristics, type of 
carrier, and the type of liquid vehicle used in the formulation. Therefore, 
these should be optimized, and its effect on dissolution rate should be 
evaluated [8,9].
The main components of liquisolid systems are carrier material, coating 
material, non-volatile solvent, and disintegrant. Carrier material such as 
various grades of sorbitol, cellulose, lactose, and starch holds sufficient 
adsorption property [10]. Coating materials are highly adsorptive and 
usually in very fine particle size range. These are various grades of 
colloidal silica such as Syloid 
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XDP, Syloid 244FP, Cab-O-Sil, and Aerosil 200. Non-volatile liquids such 
as polysorbates, fixed oils, liquid polyethylene glycols (PEG), propylene 
glycol, glycerin, N, and N-dimethylacetamide in which drug should be 
dissolved, were selected. The type and concentration of disintegrant or 
super-disintegrant are mainly based on the objective of the study. 5% 
of disintegrant is mostly used in the formulations. For example, Sodium 
starch glycolate is the most commonly used disintegrant [5,10].
Acyclovir, an antivirus drug is used to treat virus infections caused by 
herpes zoster and herpes simplex. However, acyclovir shows limited 
therapeutic potential due to its low oral bioavailability this is due to the 
fact that it has inadequate water solubility as well as low permeability [11].
Existing treatment options available for acyclovir includes oral, 
parenteral, and topical therapy. Among these routes, topical treatment 
is not much effective due to the low acyclovir permeability in the skin 
cells. While oral route is the most effective, appropriate and patient-
compliant as compared to others but previous reports exhibited low 
and variable oral bioavailability of acyclovir and systemic adverse 
effects due to frequent oral dose administration [11].
Therefore, there is a need for advancement in the oral delivery of 
acyclovir which will prevent its systemic adverse effect and provide 
optimum drug concentration [11].
MATERIALS AND METHODS
Materials
Acyclovir API was procured from M/s Ind-Swift Laboratories, India. 
Tween 80, Tween 60, and Lactose were purchased from M/s SD Fine 
Chemicals Ltd., Mumbai, India. PEG 400 was obtained from M/s HiMedia 
Laboratories Pvt. Ltd, Mumbai, India. Microcrystalline cellulose (MCC) 
PH 102 was gifted by Colorcon Pvt. Ltd, Mumbai. Syloid XDP was gifted 
by Grace Materials Technologies, Discovery Sciences, Mumbai, India. All 
other chemicals, solvents, and reagents used were of analytical grade. 
Dissolution apparatus type II (Lab India, DS-8000, Mumbai, India), and 
Double beam ultraviolet (UV)-visible spectrophotometer (UV 1800) 
from Shimadzu Japan were used.
Methods
Solubility determination
Solubility studies were carried out in the different non-volatile solvent 
system. It helps in selection of suitable liquid vehicle for preparation of 
liquisolid compacts. Three different non-volatile solvents, i.e. PEG 400, 
Tween 60, and Tween 80 are selected. Then, saturated drug solutions 
were prepared by distributing acyclovir (50 mg) equally to a test tube 
containing 5 mL of PEG 400, Tween 80, and Tween 60 separately. 
These tubes were then put in bath sonicator for 48 h for the process of 
sonication. The solutions were taken after 48 h, and suitable dilutions 
were made (1000, 100, and 10 ppm) using distilled water. The samples 
were diluted, filtered using 0.45 µm Millipore filter and absorbance was 
noted in triplicate using UV/visible spectrophotometer at a wavelength 
of 255 nm.
Loading factor (Lf) of drug
To turn the liquid medication into free-flowing powder one carrier 
- MCC PH102 and one coating agent - Syloid XDP was used. Hence, in 
0.4 mL of liquid medication, weighed quantity of carrier (400 mg) and 
drug (50 mg) was added until a good flow of powder was achieved 
and in 0.8 mL of liquid medication, weighed quantity of coating agent 
(800 mg) and drug (100 mg) was added until good flow of powders 
of different ratios, namely 10, 20, and 30 were obtained. The Lf of the 
drug are useful parameter which helps in determination of carrier and 
coating materials amount in each formulation [12]. Therefore, the Lf of 
the batches containing Syloid XDP were calculated as per the formula 
given below in equation (1):
The formula is Lf = W/C (1)
In equation (1), W is the weight of the liquid medication in grams (g), 
and C is the weight of the carrier used.
Drug content determination in liquisolid powder sample
Acyclovir amount in the sample (dried) was estimated by dissolving 
liquisolid compact sample (e.g., containing acyclovir, Syloid XDP, and 
MCC PH 102) about 5 mg in distilled water (10 mL), and then sonicated 
for 30 min. Subsequently, the sample was filtered, and its absorbance 
reading (in triplicate) was noted using UV/visible Spectrophotometer 
at a wavelength of 255 nm [5].
Flow properties - liquisolid powders
Angle of repose
Angle of repose can be calculated with the help of a funnel placed 
on a tripod stand. This method is used to determine the frictional 
forces present in loose powder. The angle of repose is the maximum 
angle which is possible between the surface of a powder pile and the 
horizontal plane [4,13-15]. The formula for calculation of angle of 
repose is given below in equation (2).
Tan θ = h/r (2)
(In equation 2, h is the height of powder conical pile, and r is the radius 
of the conical pile base).
Bulk density
Bulk density expressed in grams per milliliter (g/mL) is the weight 
of powder divided by its bulk volume [4,15]. The equation (3) for 
determining bulk density (ρb) is:
ρb = M/Vb (3)
(In equation 3, ρb is Bulk density, M is mass of a sample in grams, and 
Vb is Bulk volume in cm3).
Tapped density
Tapped density can be defined as the mass of blend in the measuring 
cylinder divided by its tapped volume [4,15]. The equation (4) for 
determining tapped density (ρt) is:
ρt = M/Vt (4)
In equation 4, ρt is Tapped density, M is mass of blend (g), and Vt is 
Tapped volume (cm3).
Moisture content
Moisture content is a test that is taken to ensure the removal of all the 
moisture present in the liquisolid powder. It is done by putting the 
powder in Petri plates and placing them in an autoclave then checking 
their moisture content by weighing at different time intervals, i.e., after 
every 15–30 min [4,15]. The formula of moisture content is shown in 
equation (5):
Moisture content (%) = w2−w3/w2−w1×100 (5)
In equation (5), w1 is the weight of empty Petri plates, w2 is the weight 
of Petri plate with sample, and w3 is the weight of Petri plate with 
sample after drying.
Product yield
Product yield or percentage yield is the product amount which is 
calculated from limiting reactant. Limiting reactant is that reactant 
in a chemical reaction which is going to limits the amount of final 
formed product. The practical yield is the actual amount that is 
produced when a reaction is carried out [4]. The difference between 
the practical yield and theoretical yield (gram or mole) and actual 
yield (gram or mole) can be calculated from the formula given in 
equation (6):
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= ×
Practical yield Product yield 100
Theoretical yield  (6)
Preparation of acyclovir liquisolid tablet
Acyclovir liquisolid compacts were prepared by dispersed in Tween 60 
which was used as the liquid vehicle to prepare the liquid medication [4]. 
The latter was added into the mixture of carrier-coating materials with 
continuous stirring which was compressed into a liquisolid tablet using 
tablet machine manually. The acyclovir liquisolid tablets prepared 
and are compared with pure acyclovir tablets. Different formulation 
attributes affecting the liquisolid compact tablets such as carrier-type, 
different Lf were taken into account during preparation of liquisolid 
tablets [15,16].
Dissolution studies of acyclovir
In vitro, dissolution studies were performed on USP Dissolution Test 
Apparatus Type II (Lab India, DS-8000, Mumbai, India) for acyclovir 
liquisolid tablets and compared with pure acyclovir conventional 
tablet [17,18]. The amount of acyclovir release with time for 60 min was 
determined using distilled water (900 mL) as medium maintained at 
37±0.5°C at a paddle speed of 50 rpm. 10 mL aliquots were withdrawn 
from the dissolution medium at predetermined time intervals of 5, 10, 
15, 30, 45, and 60 min, respectively, and the medium was replaced with 
10 mL of distilled water to maintain the sink condition. The aliquots were 
withdrawn, filtered through membrane filter (0.45 µm) and analyzed in 
triplicate using UV/visible spectrophotometer at 255 nm [4,15,19].
For each formulation, drug release (%) is calculated using the following 
formula in equation (7):
( )= ×Sample absorbance Standard dilution Drug release %
Standard absorbance Sample dilution  (7)
RESULTS AND DISCUSSION
Standard plot of acyclovir was prepared using distilled water as a 
solvent. A range of 2–10 mcg/mL acyclovir dilutions were prepared, 
and absorbance was noted at the wavelength of 255 nm using a UV-
visible spectrophotometer, as shown in Fig. 1.
Solubility studies demonstrate that the drug acyclovir has revealed 
highest solubility in Tween 60 (i.e., 31.65 %) as compared to PEG400 
and Tween 80 (Table 1). Hence, Tween 60 was selected as the better 
solvent vehicle for preparation of liquid medication [4].
Previous literature suggested that additives improve the flow properties 
and compatibility of liquisolid formulations. Lf (Table 2) was calculated. 
From Table 2, it was concluded that the liquisolid sample of ratio 10 has 
the highest Lf.
The absorbance for pure drug and liquisolid powder of coating agent 
only was observed at 255 nm, and the results are shown in Table 3. 
From the absorbance reading, the acyclovir content in liquisolid tablet 
was found to be 77.44% [4].
The flow properties, i.e., angle of repose, bulk density, and tapped 
density are calculated and reported in Tables 4 and 5, respectively. In 
Table 5, the highest bulk density was seen in liquisolid powder of ratio 
30 and the highest tapped density in the liquisolid sample with coating 
agent only [4].
Fig. 1: Standard curve of acyclovir in distilled water at 255 nm
Table 1: Solubility studies of acyclovir in non-volatile liquid 
vehicle
S. No Non-volatile liquid vehicle Ppm Solubility (%)
1 PEG 400 100 24.5
10 10.8
2 Tween 60 100 31.65
10 18.5
3 Tween 80 100 26.5
10 17.8
PEG: Polyethylene glycols
Table 2: Lf of different liquisolid ratios
Liquisolid sample Lf (W/C)
In grams In µL
Liquisolid sample with coating agent only 0.4 400
Liquisolid sample of ratio 10 (coating+carrier) 1.68 1680
Liquisolid sample of ratio 20 (coating+carrier) 1.64 1640
Liquisolid sample of ratio 30 (coating+carrier) 1.63 1630
Lf: Loading factor





Actual drug content (%) in liquisolid powder 77.44
Table 4: Angle of repose of liquisolid powders (Data in 
triplicate)
1. Liquisolid powder with coating agent only:
1. h1=0.5 cm  r1=3.1 cm
2. h2=0.4 cm  r2=3.6 cm
3. h3=0.6 cm  r3=4.0 cm
Average, height (h) = 0.5 cm, radius (r) = 3.6 cm
2.  Liquisolid formulation having carrier to coating ratio 10:
1. h1=0.9 cm  r1=4.2 cm
2. h2=1 cm  r2=3.8 cm
3. h3=1 cm  r3=4 cm
Average, height (h) = 0.96 cm, radius (r) = 4 cm
3.  Liquisolid of having carrier to coating ratio 20:
1. h1=1 cm  r1=3.9cm
2. h2=0.8 cm  r2=4.2cm
3. h3=1 cm  r3=3.7cm
Average, height (h) = 0.93 cm,  radius (r) = 3.9 cm
4. Liquisolid of having carrier to coating ratio 30:
1. h1=1 cm  r1=3.6cm
2. h2=1.2 cm  r2=3.8cm
3. h3=1.2 cm  r3=3.6cm
Average, height (h) = 1.13 cm,  radius (r) = 3.67 cm
Liquisolid sample Angle of repose (°)
With coating agent only 7.9
With ratio 10 13.5
With ratio 20 13.41
With ratio 30 17.11
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Table 6 depicts that the liquisolid sample with the coating agent only 
had the highest amount of moisture content loss [15]. Among the 
various carrier to coating ratios used, the liquisolid powders having 
lowest carrier to coating ratio (i.e., R = 10) showed the lowest angle of 
repose value.
Table 7 shows that the highest product yield was seen in liquisolid 
powder of ratio 20.
The dissolution results of unprocessed acyclovir and its liquisolid 
formulations prepared by varying the carrier to coating ratio are shown 
in Fig. 2. The results clearly indicated that the dissolution profile of drug 
present in liquisolid formulations got significantly increased (p<0.05) 
as that unprocessed drug. It was observed that only 66% of drug got 
released from the unprocessed powder in 60 min, whereas, more than 
80% drug got released within 5 min from all the liquisolid formulations. 
Such observations clearly revealed that acyclovir got completely 
dissolved in tween-80 and remain adsorbed in solution state in the 
matrix of carrier and coating material [19]. Once they were introduced 
in the dissolution medium, the homogeneous solution of tween-80 and 
drug got completely miscible with the medium. Among the various 
ratios, the liquisolid formulations having R equal to 10 showed the 
higher extent of drug release. This could be probably due to that fact 
that Syloid XDP is amorphous silica and has higher surface area as that 
of MCC PH 102. In lower ratio, the amount of Syloid XDP was more than 
MCC PH 102 which would have enhanced the wettability of formulation 
in the medium [20,21].
CONCLUSION
This current study provides evidence that due to the liquisolid 
technique now it is possible to increase the dissolution of poorly soluble 
drug. The liquisolid tablets of acyclovir exhibit a remarkably improved 
dissolution rate in comparison with acyclovir plain tablet. Results of 
dissolution study showed greater dissolution rate of acyclovir from 
liquisolid compacts. The results are affected by changing the ratio of the 
carrier to coating material.
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